Intrinsiqq
Lakefront Biotherapeutics logo

Lakefront Biotherapeutics Financials

LKFT.XAMS

Compare

All currency values in € millions unless otherwise noted

Income Statement
TTM
DEC 2025
Revenues
Revenue€991€1,112
Cost of Revenue€25€30
Gross Profit€965€1,083
Total Operating Expenses€355€581
Operating Income€610€501
Non-Operating
Net Interest Expense–-€2
Income Tax Expense-€17-€19
Net Income
Net Income€597€321
Per Share Data
Revenue Per Share€15.04€16.88
EPS (Basic)€9.06€4.87
EPS (Diluted)€9.06€4.87
Shares Outstanding65.9M65.9M

Lakefront Biotherapeutics (LKFT.XAMS) financials: revenue, profit and margins

Lakefront Biotherapeutics (LKFT.XAMS) generated about €991 million in revenue and €597 million in net income (a 60.2% net margin) over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Lakefront Biotherapeutics's (LKFT.XAMS) revenue?+

Lakefront Biotherapeutics generated about €991 million in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Lakefront Biotherapeutics profitable?+

Yes, Lakefront Biotherapeutics reported about €597 million in net income over the trailing twelve months, a net profit margin of roughly 60.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Lakefront Biotherapeutics's profit margins?+

Lakefront Biotherapeutics runs a gross margin of about 97.5%, an operating margin of about 61.6%, a net margin of about 60.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with LKFT.XAMS

CompareIntrinsic value
GLPGGalapagos NV American Depositary Receipt
$33.39-2.00%61
ASNDAscendis Pharma A/S
$252.73-1.26%59
LMRILumexa Imaging Holdings, Inc.
$14.10+0.25%42
SFL.XMILSafilo Group S.p.A.
€2.06-6.78%69
SUS.XSTOSurgical Science Sweden AB
kr 59.75+0.76%37
DOCM.XSWXDocMorris AG
CHF 18.63-0.90%26
FAGR.XBRUFagron NV
€24.65+1.02%78
DMP.XETRDermapharm Holding SE
€32.75-2.09%49

Held by ETFs

LKFT.XAMS is in 10 US ETFs. The largest of them, with LKFT.XAMS's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing LKFT.XAMS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.